Abstract: A senotherapeutic compound including a synthetic derivative of flavones, according to the formula (I) as indicated below: in which at least two of R2-R8 are H, and the remainder are individually selected from: H, OH, R1, OR1, NO2, NH2, NHR1, F, Cl, Br, I, where R1 is a radical.

Abstract: A senotherapeutic substance including flavonoids, fatty acids, and, preferably, phenolic acids and/or vitamins. The substance may be used for the manufacture of a medicament for senotherapeutic use.

Abstract: The present invention concerns an extract from pomegranate (Punica granatum L), specifically obtained from one or more immature pomegranate fruits. This extract is obtained through an extraction process including steps a)-d) as described in the text and it may contain gallotannins, ellagitannins, ellagic acid derivatives and granatins. Pharmaceutical and nutraceutical compositions and food supplements comprising this extract fall within the scope of the present invention as well as their use in various fields, more specifically for the treatment of tumors.

Abstract: Provided is a medical compound including a synthetic flavone derivative, according to the formula (I) with allotment in position C-3 of a group as shown below: wherein at least two of R2-R6 are H, and the remaining are independently selected from: H, OH, R1, OR1, NO2, NH2, NHR1, F, Cl, Br, I, where R1 is a radical.

Abstract: Proliferation of colorectal, gastric and esophageal cancer cells is inhibited by administering ST receptor ligand. The number of ST receptor molecules on the surface of a colorectal cell or metastasized colorectal cancer cell are increased by administering an ST receptor ligand such that ligand comes into contact with an ST receptor on the surface of the colorectal cell. Pharmaceutical compositions comprise sterile, pyrogen free ST receptor ligand and a pharmaceutically acceptable carrier or diluent. Metastasized colorectal cancer is treated or imaged by increasing the number of ST receptor molecules on the surface of a metastasized colorectal cancer cell and then administering a pharmaceutical composition containing components that target the ST receptor for delivery of a therapeutic agent or imaging agent. Methods of detecting metastasized colorectal cancer are disclosed. Methods of delivering active compounds to a colorectal cell in an individual are disclosed.

Abstract: Proliferation of colorectal, gastric and esophageal cancer cells is inhibited by administering ST receptor ligand. The number of ST receptor molecules on the surface of a colorectal cell or metastasized colorectal cancer cell are increased by administering an ST receptor ligand such that ligand comes into contact with an ST receptor on the surface of the colorectal cell. Pharmaceutical compositions comprise sterile, pyrogen free ST receptor ligand and a pharmaceutically acceptable carrier or diluent. Metastasized colorectal cancer is treated or imaged by increasing the number of ST receptor molecules on the surface of a metastasized colorectal cancer cell and then administering a pharmaceutical composition containing components that target the ST receptor for delivery of a therapeutic agent or imaging agent. Methods of detecting metastasized colorectal cancer are disclosed. Methods of delivering active compounds to a colorectal cell in an individual are disclosed.